Indications of anakinra

被引：17

作者：

Chauffier, Karine ^{[1
]}

London, Jonathan ^{[1
]}

Beaudouin, Constance ^{[1
]}

Fautrel, Bruno ^{[1
]}

机构：

[1] Univ Paris 06, AP HP, GH Pitie Salpetriere, Serv Rhumatol,UFR Med, F-75013 Paris, France

来源：

PRESSE MEDICALE | 2009年 / 38卷 / 05期

关键词：

INTERLEUKIN-1 RECEPTOR ANTAGONIST; JUVENILE IDIOPATHIC ARTHRITIS; ACTIVE RHEUMATOID-ARTHRITIS; AUTOINFLAMMATORY DISEASES; DOUBLE-BLIND; METHOTREXATE; COMBINATION; MULTICENTER; RESISTANT; EFFICACY;

D O I：

10.1016/j.lpm.2009.01.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The efficacy of anakinra on both RA-related symptoms and structural damage has been demonstrated in several randomized controlled trials. However, its interest seems limited with regards to other biologic agents. Anakinra seems promising in the treatment of childhood or adult onset Still disease, after the failure of both high dose steroids and methotrexate. The efficacy of anakinra is dramatic in several hereditary autoinflammatory syndromes. Anakinra could be an interesting drug for the treatment of neutrophilic dermatosis or relapsing chondritis, refractory to conventional agents. Injection site reactions and infections are the 2 main anakinra-related side effects.

引用

页码：799 / 807

页数：9

共 31 条

[1] Biological role of interleukin 1 receptor antagonist isoforms [J].

Arend, WP ;

Guthridge, CJ .

ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 :60-64

[2]

Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO

[3]

2-U

[4] Sweet's syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis [J].

Cohen, Philip R. .

ORPHANET JOURNAL OF RARE DISEASES, 2007, 2 (1)

[5] Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial [J].

Cohen, S ;

Hurd, E ;

Cush, J ;

Schiff, M ;

Weinblatt, ME ;

Moreland, LW ;

Kremer, J ;

Bear, MB ;

Rich, WJ ;

McCabe, D .

ARTHRITIS AND RHEUMATISM, 2002, 46 (03) :614-624

[6] A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate [J].

Cohen, SB ;

Moreland, LW ;

Cush, JJ ;

Greenwald, MW ;

Block, S ;

Shergy, WJ ;

Hanrahan, PS ;

Khraishi, MM ;

Patel, A ;

Sun, G ;

Bear, MB .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (09) :1062-1068

[7] Targeting interleukin-1 in the treatment of rheumatoid arthritis [J].

Dayer, JM ;

Bresnihan, B .

ARTHRITIS AND RHEUMATISM, 2002, 46 (03) :574-578

[8] Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome [J].

Delluc, A. ;

Limal, N. ;

Puechal, X. ;

Frances, C. ;

Piette, J. C. ;

Cacoub, P. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) :278-278

[9] Anakinra for flares of pyogenic arthritis in PAPA syndrome [J].

Dierselhuis, MP ;

Frenkel, J ;

Wulffraat, NM ;

Boelens, JJ .

RHEUMATOLOGY, 2005, 44 (03) :406-408

[10] Autoinflammatory diseases - Clinical and genetic advances [J].

Farasat, Sharifeh ;

Aksentijevich, Ivona ;

Toro, Jorge R. .

ARCHIVES OF DERMATOLOGY, 2008, 144 (03) :392-402

← 1 2 3 4 →